Philadelphia, Pennsylvania – Plexus Ventures announces the successful completion of a recent out-licensing project on behalf of Celon Pharma.
Additional details regarding the transaction, taken from Lupin Limited’s February 17, 2015 press release are included below:
Lupin and Celon Announce Strategic Development and Licensing Agreement for Generic Advair Diskus®
Mumbai, Baltimore, February 17, 2015: Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced today that they have entered into a definitive agreement under which the companies will jointly develop fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline’s Advair Diskus®. Lupin will be responsible for commercialization of the product. Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico, and other key markets. GlaxoSmithKline’s Advair Diskus® had global sales of over USD 7 billion as of last fiscal.
Lupin CEO Vinita Gupta said, “This collaboration is an important milestone in Lupin’s efforts to evolve its global inhalation pipeline. We are very pleased to partner with Celon given their experience in the development and manufacturing of fluticasone/salmeterol DPI in Europe. This coupled with Lupin’s expertise in inhalation product development and commercialization in the US and other markets will accelerate the development of generic Advair Diskus® for global markets. We look forward to providing access to high quality, affordable fluticasone/salmeterol DPI as part of our strategy to deliver inhaled products to key markets.
Celon’s CEO and Managing Director Maciej Wieczorek, Ph.D. said, “Our scientific and technical teams look forward to collaborating with Lupin to bring this product to major markets outside of Poland. We are enthusiastic and believe that both the companies would work together to complete a time bound research and development program to ensure successful registration in targeted markets, for Lupin to effectively commercialize the product.”